FDA re­vis­es 1999 draft guid­ance on pop­u­la­tion phar­ma­co­ki­net­ics

The FDA on Thurs­day re­leased re­vised draft guid­ance to help keep spon­sors in­formed on the da­ta and mod­el re­quire­ments for pop­u­la­tion phar­ma­co­ki­net­ics (PK) analy­ses sub­mit­ted as part of new drug ap­pli­ca­tions and bi­o­log­ic li­cense ap­pli­ca­tions.

Since the orig­i­nal pop­u­la­tion PK guid­ance was pub­lished in 1999, the FDA says the num­ber of ap­pli­ca­tions rel­e­vant for pop­u­la­tion PK analy­sis has in­creased and, “The so­phis­ti­ca­tion and re­li­a­bil­i­ty of pop­u­la­tion PK analy­sis meth­ods have im­proved.”

Specif­i­cal­ly, the re­vised, 23-page draft guid­ance in­cludes a de­scrip­tion of the types of sci­en­tif­ic and reg­u­la­to­ry ques­tions ap­pro­pri­ate for pop­u­la­tion PK analy­sis and out­lines the FDA’s rec­om­men­da­tions for da­ta analy­sis and mod­el­ing. Rec­om­men­da­tions on the for­mat and con­tent of pop­u­la­tion PK re­ports sub­mit­ted to the FDA as well as any la­bel­ing state­ments in­formed by the re­sults of these analy­ses are al­so in­clud­ed.

“Pop­u­la­tion PK analy­sis typ­i­cal­ly in­cludes da­ta di­rect­ly col­lect­ed from pa­tients, al­low­ing an as­sess­ment of mul­ti­ple in­trin­sic and ex­trin­sic fac­tors that are not oth­er­wise eval­u­at­ed in healthy vol­un­teers,” the draft says. “In ad­di­tion, the rel­a­tive­ly large num­bers of pa­tients in­clud­ed in pop­u­la­tion PK analy­sis may im­prove the pre­ci­sion of the es­ti­mat­ed ef­fect of the fac­tors that af­fect drug ex­po­sures and con­firm which fac­tors do not change drug ex­po­sures.”

The draft ad­dress­es the ap­pli­ca­tion of pop­u­la­tion PK analy­sis in drug de­vel­op­ment and to in­form drug use, with fur­ther dis­cus­sions on se­lect­ing dos­ing reg­i­mens to be test­ed in clin­i­cal tri­als, de­riv­ing ex­po­sure met­rics for con­duct­ing ex­po­sure-re­sponse analy­sis, pe­di­atric study de­signs and drug-drug in­ter­ac­tions, among oth­er sec­tions.

The sec­tion on da­ta analy­sis al­so pro­vides fur­ther help on the method­olog­i­cal as­pects of pop­u­la­tion PK analy­sis and in­cludes a dis­cus­sion of sim­u­la­tions based on pop­u­la­tion PK mod­els, which touch­es on fixed-ef­fect es­ti­mates and es­ti­mates of be­tween-sub­ject vari­abil­i­ty.

At the end of the draft, the FDA al­so in­cludes a ta­ble ex­plain­ing the ex­pect­ed con­tent in each sec­tion of the pop­u­la­tion PK study re­port.

Pop­u­la­tion Phar­ma­co­ki­net­ics: Draft Guid­ance for In­dus­try


First pub­lished in Reg­u­la­to­ry Fo­cus™ by the Reg­u­la­to­ry Af­fairs Pro­fes­sion­als So­ci­ety, the largest glob­al or­ga­ni­za­tion of and for those in­volved with the reg­u­la­tion of health­care prod­ucts. Click here for more in­for­ma­tion.

So­cial im­age: FDA, AP Im­ages

Author

Zachary Brennan

managing editor, RAPS

Hal Barron, GSK

Break­ing the death spi­ral: Hal Bar­ron talks about trans­form­ing the mori­bund R&D cul­ture at GSK in a crit­i­cal year for the late-stage pipeline

Just ahead of GlaxoSmithKline’s Q2 update on Wednesday, science chief Hal Barron is making the rounds to talk up the pharma giant’s late-stage strategy as the top execs continue to woo back a deeply skeptical investor group while pushing through a whole new R&D culture.

And that’s not easy, Barron is quick to note. He told the Financial Times:

I think that culture, to some extent, is as hard, in fact even harder, than doing the science.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Michel Vounatsos, Getty Images

UP­DAT­ED: Stay tuned: Bio­gen’s num­bers are great — it’s their wor­ri­some fu­ture that leaves an­a­lysts skit­tish

Biogen came out with an upbeat assessment of their Q2 numbers today, discounting the arrival of a key rival for its blockbuster Spinraza franchise. But the top execs remain grimly determined to not say much anything new about the sore points that have dragged down its stock, including the future of its big investment in Alzheimer’s or how it plans to invest the considerable cash that the big biotech continues to reap.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

PACT Phar­ma says it's per­fect­ed the tech to se­lect neoanti­gens for per­son­al­ized ther­a­py — now on­to the clin­ic

At PACT Pharma, the lofty goal to unleash a “tsunami” of T cells personalized for each patient has hinged on the ability to correctly identify the neoantigens that form something of a fingerprint for each tumor, and extract the small group of T cells primed to attack the cancer. It still has a long way to go testing a treatment in humans, but the biotech says it has nailed that highly technical piece of the process.

UP­DAT­ED: My­ovan­t's uter­ine fi­broid drug looks com­pet­i­tive in PhI­II — but can they van­quish mighty Ab­b­Vie?

Vivek Ramaswamy’s Myovant $MYOV has closely matched its positive first round of Phase III data for their uterine fibroid drug relugolix, setting up a head-to-head rivalry with pharma giant AbbVie as the little biotech steers to the market with a planned filing in Q4.

Here’s how Myovant plans to prevail over the AbbVie $ABBV empire.

In the study, 71.2% of women receiving once-daily relugolix combination therapy achieved the clinical response they were looking for, compared to only 14.7% in the control arm. The data comfortably reflected the same outcomes in the first Phase III — 73.4% of women receiving once-daily oral relugolix combination therapy achieved the responder criteria compared with 18.9% of women receiving placebo — which will reassure regulators that they are getting the carefully randomized data that qualifies for the FDA’s gold standard for success.

Lit­tle Mar­i­nus sees its shares eclipsed as the Sage ri­val fails to com­pare on PPD in PhII

The executive team at Sage $SAGE have skirted another potential pitfall on its way to racking up a big future for its depression drug Zulresso.

Little Marinus Pharmaceuticals $MRNS had sought to challenge the Sage drug with an IV formulation — followed by an oral version — of ganaxolone for postpartum depression. But researchers say their Phase II study failed to positively differentiate itself from a placebo at 28 days — leaving them to hold up “clinically meaningful” data within the first day of administration compared to the control arm.

Roche cuts loose Tam­i­flu OTC rights, hand­ing Sanofi the keys as the phar­ma gi­ant dou­bles down on Xofluza

Roche set out to make a better flu medicine than Tamiflu as that franchise was headed to a generic showdown. Now they’ll see just how well Xofluza stacks up against the mainstay drug after handing off over-the-counter rights in the US to Sanofi.

Sanofi $SNY says it will now step in to negotiate a deal with the FDA to steer Tamiflu into the OTC market, a role that could well involve new studies to ease passage of the drug out of doctor’s hands and into the consumer end of the market. And the French pharma giant will have first dibs over “selected” OTC markets around the world as they push ahead.

Aca­dia is mak­ing the best of it, but their lat­est PhI­II Nu­plazid study is a bust

Acadia’s late-stage program to widen the commercial prospects for Nuplazid has hit a wall. The biotech reported that their Phase III ENHANCE trial flat failed. And while they $ACAD did their best to cherry pick positive data wherever they can be found, this is a clear setback for the biotech.

With close to 400 patients enrolled, researchers said the drug flunked the primary endpoint as an adjunctive therapy for patients with an inadequate response to antipsychotic therapy. The p-value was an ugly 0.0940 on the Positive and Negative Syndrome Scale, which the company called out as a positive trend.

Their shares slid 12% on the news, good for a $426 million hit on a $3.7 billion market cap at close.

Endpoints News

Basic subscription required

Unlock this story instantly and join 55,200+ biopharma pros reading Endpoints daily — and it's free.

Some Big Phar­mas stepped up their game on da­ta trans­paren­cy — but which flunked the test?

The nonprofit Bioethics International has come out with their latest scorecard on data transparency among the big biopharmas in the industry — flagging a few standouts while spotlighting some laggards who are continuing to underperform.

Now in its third year, the nonprofit created a new set of standards with Yale School of Medicine and Stanford Law School to evaluate the track record on trial registration, results reporting, publication and data-sharing practice.

Busy Gilead crew throws strug­gling biotech a life­line, with some cash up­front and hun­dreds of mil­lions in biobucks for HIV deal

Durect $DRRX got a badly needed shot in the arm Monday morning as Gilead’s busy BD team lined up access to its extended-release platform tech for HIV and hepatitis B.

Gilead, a leader in the HIV sector, is paying a modest $25 million in cash for the right to jump on the platform at Durect, which has been using its technology to come up with an extended-release version of bupivacaine. The FDA rejected that in 2014, but Durect has been working on a comeback.